Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Vijaya Diagnostic vs Krsnaa Diagnostics on Price, Valuation, Q2 FY27 Results and Risks
- November 10, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Previous close: Dr Lal PathLabs Rs 2,008.80, Metropolis Healthcare Rs 575.90, Thyrocare Rs 498.95, Vijaya Diagnostic Rs 1,466.60, Krsnaa Diagnostics Rs 485.35.
Quick Answer
This diagnostics stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, Vijaya Diagnostic and Krsnaa Diagnostics. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,837 crore. Thyrocare reports the highest return on equity at 31.66%. Premium multiples are common among diagnostics chains, so check whether returns and test volumes support each one.
Diagnostics stocks compared here means Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, Vijaya Diagnostic and Krsnaa Diagnostics on one page, checked on previous close, market value, valuation and the latest quarterly numbers. All five run pathology or radiology centres, but they differ in size, in how much they earn from home collection and wellness packages, and in how they reach patients, which is exactly why a side-by-side look helps.
All five diagnostics companies have filed their September 2026 quarter, so every result below is Q2 FY27. Diagnostics chains follow healthcare spending and the pace of preventive checks, so a glance at the Nifty Midcap 100 page and the Sensex page before you read the tables gives useful backdrop.
Click Here – Get Free Investment Predictions
Diagnostics Stocks Compared: The Five Lab Chains on the List
The diagnostics stocks compared here are Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, Vijaya Diagnostic and Krsnaa Diagnostics. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,837 crore. Previous closes run from Rs 485.35 for Krsnaa Diagnostics to Rs 2,008.80 for Dr Lal PathLabs, which is why a side-by-side look at value rather than price is more useful. This diagnostics stocks compared list is the base for every table that follows.
| Stock | Previous close (Rs) | Market cap (Rs crore) |
|---|---|---|
| Dr Lal PathLabs | 2,008.80 | 33,837 |
| Metropolis Healthcare | 575.90 | 12,074 |
| Thyrocare | 498.95 | 7,740 |
| Vijaya Diagnostic | 1,466.60 | 15,178 |
| Krsnaa Diagnostics | 485.35 | 1,601 |
A quick look at the business behind each ticker puts the numbers in context. Dr Lal PathLabs runs one of the largest networks of diagnostic labs and collection centres in the country, while Metropolis Healthcare runs a national chain of pathology labs and patient service centres. Thyrocare runs a large central lab and sells wellness and diagnostic tests through partners and online channels, and Vijaya Diagnostic runs diagnostic centres for pathology and radiology tests, with a strong base in southern India. To compare diagnostics stocks properly, line up price to earnings, return on equity and operating margin before forming a view.
Rounding out the group, Krsnaa Diagnostics runs diagnostic centres for pathology and radiology tests, including in government hospitals. A fair diagnostics stock comparison looks at what each company actually earns from, not only at the share price. National chains, partner-led models and hospital-based models belong in separate mental boxes whenever you compare diagnostics stocks fairly.
Diagnostics Stocks Valuation: Multiples, Returns and Payouts
Krsnaa Diagnostics trades at the lowest price to earnings ratio in this group at 16.32. Thyrocare reports the highest return on equity at 31.66%. Krsnaa Diagnostics has the lowest price to book value at 1.54. These diagnostics stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this diagnostics stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.
| Stock | Price to earnings | Price to book | ROE (%) | Dividend yield (%) | Debt to equity |
|---|---|---|---|---|---|
| Dr Lal PathLabs | 57.55 | 12.33 | 21.32 | 1.02 | 0.09 |
| Metropolis Healthcare | 53.57 | 7.36 | 13.66 | 0.86 | 0.16 |
| Thyrocare | 54.03 | 13.98 | 31.66 | 2.88 | 0.10 |
| Vijaya Diagnostic | 74.50 | 14.36 | 19.26 | 0.14 | 0.48 |
| Krsnaa Diagnostics | 16.32 | 1.54 | 9.45 | 0.41 | 0.57 |
Diagnostics stocks usually trade at premium price to earnings multiples because investors pay for steady test volumes and a long runway of new centres. Return on equity and dividend yield help you judge whether a premium is earned and how much each lab chain pays back to shareholders. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple diagnostics stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.
In this group, price to earnings runs from 16.32 for Krsnaa Diagnostics to 74.50 for Vijaya Diagnostic. Thyrocare offers the highest dividend yield at 2.88%. The industry price to earnings for this group stands at 61.92, which is the benchmark each stock above can be read against. The industry price to earnings is a handy anchor: a diagnostics stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built diagnostics stock comparison also notes that wellness packages and seasonal illness can move volumes between quarters. Run the same diagnostics stock comparison on your own watchlist and the pattern in these numbers will be easier to spot. Whenever you compare diagnostics stocks, note whether a premium is backed by returns or only by size.
Diagnostics Stocks Q2 FY27 Results: Revenue and Profit Check
All of the five diagnostics stocks compared have filed Q2 FY27 numbers. Krsnaa Diagnostics posted the fastest revenue growth at 31.9% year on year. Metropolis Healthcare showed the sharpest rise in net profit at 42.7%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this diagnostics stocks compared review as a snapshot of one quarter, not a verdict on any lab chain.
| Stock | Q2 FY27 revenue (Rs crore) | Q2 FY26 revenue (Rs crore) | Q2 FY27 net profit (Rs crore) | Q2 FY26 net profit (Rs crore) |
|---|---|---|---|---|
| Dr Lal PathLabs | 908.2 | 755.4 | 193.9 | 152.2 |
| Metropolis Healthcare | 505.3 | 430.1 | 75.5 | 52.9 |
| Thyrocare | 274.4 | 219.6 | ||
| Vijaya Diagnostic | 260.3 | 207.8 | 59.5 | 43.3 |
| Krsnaa Diagnostics | 277.1 | 210.2 | 24.6 | 23.9 |
Dr Lal PathLabs Results Snapshot
Dr Lal PathLabs reported Q2 FY27 revenue of Rs 908.2 crore, compared with Rs 755.4 crore a year earlier, a rise of 20.2%. Net profit rose 27.4% to Rs 193.9 crore from Rs 152.2 crore. Operating margin expanded to 36.0% from 34.1% a year ago.
Metropolis Healthcare Results Snapshot
In the September 2026 quarter, Metropolis Healthcare booked revenue of Rs 505.3 crore against Rs 430.1 crore in the same quarter last year, a rise of 17.5%. Net profit rose 42.7% to Rs 75.5 crore from Rs 52.9 crore. Operating margin expanded to 28.7% from 25.4% a year ago.
Thyrocare Results Snapshot
Thyrocare’s Q2 FY27 top line stood at Rs 274.4 crore, versus Rs 219.6 crore in Q2 FY26, a rise of 25.0%.
Vijaya Diagnostic Results Snapshot
Vijaya Diagnostic reported Q2 FY27 revenue of Rs 260.3 crore, compared with Rs 207.8 crore a year earlier, a rise of 25.3%. Net profit rose 37.4% to Rs 59.5 crore from Rs 43.3 crore. Operating margin expanded to 46.1% from 43.7% a year ago. Earnings per share for the quarter rose to Rs 5.76 from Rs 4.20.
Krsnaa Diagnostics Results Snapshot
In the September 2026 quarter, Krsnaa Diagnostics booked revenue of Rs 277.1 crore against Rs 210.2 crore in the same quarter last year, a rise of 31.9%. Net profit rose 2.7% to Rs 24.6 crore from Rs 23.9 crore. Earnings per share for the quarter rose to Rs 7.54 from Rs 7.25.
Diagnostics results depend on test volumes, revenue per patient and the share of wellness packages, so profit can look different from revenue in a single quarter. That is why a diagnostics stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a diagnostics stocks compared review becomes a map of the sector rather than a price list. When you compare diagnostics stocks after each result season, track how operating margin changes from one quarter to the next. A diagnostics stock comparison built on one quarter of data is a starting point, and the next set of results will update it.
Diagnostics Stocks Compared Two at a Time: Three Pairings
Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare diagnostics stocks two at a time.
Dr Lal PathLabs vs Metropolis Healthcare
Dr Lal PathLabs and Metropolis Healthcare are two of the best-known national pathology chains, so they are the natural pair for anyone who wants exposure to organised lab testing. Dr Lal PathLabs is about 2.8 times the size of Metropolis Healthcare by market capitalisation, at Rs 33,837 crore against Rs 12,074 crore. On price to earnings, Metropolis Healthcare carries the lower multiple at 53.57 against 57.55 for Dr Lal PathLabs. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 13.66% for Metropolis Healthcare. Both are adding collection points and wellness packages, so read growth next to valuation before you judge either multiple.
Thyrocare vs Vijaya Diagnostic
Thyrocare runs a central lab and sells tests through partners, while Vijaya Diagnostic runs its own centres with a strong base in southern India. On price to earnings, Thyrocare carries the lower multiple at 54.03 against 74.50 for Vijaya Diagnostic. Thyrocare reports the higher return on equity, at 31.66% against 19.26% for Vijaya Diagnostic. For dividend income, Thyrocare offers 2.88% against 0.14% at Vijaya Diagnostic. A partner-led model and an owned-centre model earn differently, so read the business mix before you read the ratio.
Krsnaa Diagnostics vs Dr Lal PathLabs
Krsnaa Diagnostics runs centres inside government hospitals, while Dr Lal PathLabs serves retail patients through its own network. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 9.45% for Krsnaa Diagnostics. For dividend income, Dr Lal PathLabs offers 1.02% against 0.41% at Krsnaa Diagnostics. In Q2 FY27, Krsnaa Diagnostics grew revenue faster, at 31.9% year on year against 20.2% for Dr Lal PathLabs. A public-hospital contract model and a retail model are priced differently, so read returns next to valuation before you judge either.
Best Diagnostics Stocks for Each Type of Investor
If you are asking which of the best diagnostics stocks here suits you, the answer depends on what you value. The table below shows who leads on each measure today, which is the fairest way to answer without naming a single winner. Any diagnostics stocks compared table can mislead if you stop at one row, because each lab chain leads on a different measure.
| If you care most about | Start your research with | The number |
|---|---|---|
| Lowest price to earnings | Krsnaa Diagnostics | 16.32 |
| Highest return on equity | Thyrocare | 31.66% |
| Highest dividend yield | Thyrocare | 2.88% |
| Lowest price to book value | Krsnaa Diagnostics | 1.54 |
| Largest by market capitalisation | Dr Lal PathLabs | Rs 33,837 crore |
| Fastest Q2 FY27 revenue growth | Krsnaa Diagnostics | 31.9% |
| Sharpest Q2 FY27 net profit rise | Metropolis Healthcare | 42.7% |
No single name tops every row, which is exactly why a diagnostics stock comparison helps. Size, returns, payouts and valuation each point to a different lab chain, so decide what matters most to you before you rank the numbers.
What Is Driving Demand for Diagnostic Tests Right Now?
More people now get routine health checks, and doctors order more tests for lifestyle conditions. Organised chains gain as patients move from small local labs to brands that offer quality checks and home collection. Knowing what moves test volumes and centre additions helps you compare diagnostics stocks with the right questions in mind.
Test volumes, revenue per patient and operating margin decide how well a lab chain turns growth into profit. Chains that add collection centres and wellness packages can spread fixed costs over more tests. A good diagnostics stocks compared routine therefore tracks test volumes, revenue per patient and new centres.
Risks to Weigh When You Compare Diagnostics Stocks
Diagnostics stocks depend on test volumes, pricing pressure from online players and the pace of new centre openings. Wellness packages can be seasonal. Read each filing for volume, revenue per patient and margin commentary before you compare them. Every diagnostics stock comparison has blind spots, and for this group the biggest is test volumes and centre additions.
Because test volumes, revenue per patient and new centres drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this diagnostics stocks compared guide a balanced starting point.
How to Compare Diagnostics Stocks and Build a Shortlist
Start by deciding whether you want a national chain, a regional specialist or a model built around government hospitals, because each responds to different triggers. National chains reward readers who track test volumes and wellness packages, while regional names reward those who track new centre openings. Done step by step, this diagnostics stocks compared routine becomes repeatable rather than a one-off exercise.
Then check valuation and payouts, because premium multiples leave less room for slips and dividend yield differs widely across the group. Spreading your attention across one national chain and one regional name is a simple way to see both sides of the sector. Keep the shortlist of best diagnostics stocks short enough that you can actually follow each company’s quarterly results. When you compare diagnostics stocks again after new results, update only the rows that changed instead of starting over.
The Univest stock screener lets you filter diagnostics stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this diagnostics stocks compared page after the next set of results to see which numbers have moved.
Check the Univest Screener for live diagnostics stock data
Download the Univest iOS App or Univest Android App to track these diagnostics stocks live.
Conclusion: Diagnostics Stocks Compared at a Glance
This diagnostics stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Dr Lal PathLabs leads on size and Thyrocare leads on return on equity, while the others bring their own strengths. Treat the diagnostics stocks Q2 FY27 results and diagnostics stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare diagnostics stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Diagnostics Stocks Compared
Which are the top diagnostics stocks compared in this article?
Ans. The diagnostics stocks compared in this article are Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, Vijaya Diagnostic and Krsnaa Diagnostics. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so you get a clear side-by-side starting point before you open any single company’s filings in more depth.
Which diagnostics stock has the highest market capitalisation?
Ans. Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,837 crore. Vijaya Diagnostic follows at Rs 15,178 crore. Market capitalisation is the total value the market places on a company and moves with the share price every day, so check the live figure before you rely on it.
Which of these diagnostics stocks has the lowest price to earnings ratio?
Ans. On diagnostics stocks valuation, Krsnaa Diagnostics has the lowest price to earnings ratio among these diagnostics stocks at 16.32, based on the latest reported earnings. Vijaya Diagnostic sits at the other end at 74.50. A lower multiple is not automatically better, since growth, margins and business quality all influence what investors are willing to pay.
Which diagnostics stock has the highest return on equity?
Ans. Thyrocare reports the highest return on equity in this group at 31.66%. Return on equity shows how much profit a company earns on shareholder funds, so a higher figure usually points to efficient use of capital. Compare it over several years, and keep debt levels in mind, because heavy borrowing can lift the ratio.
How did diagnostics stocks perform in Q2 FY27 results?
Ans. All of the five names have filed Q2 FY27 numbers in our data. Krsnaa Diagnostics recorded the fastest revenue growth at 31.9% year on year. Metropolis Healthcare showed the sharpest net profit rise at 42.7%. For diagnostics stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.
What are the main risks when you compare diagnostics stocks?
Ans. Diagnostics stocks depend on test volumes, pricing pressure from online players and the pace of new centre openings. Wellness packages can be seasonal. Read each filing for volume, revenue per patient and margin commentary before you compare them. Keep an eye on test volumes, revenue per patient and new centres.
Which metrics matter most when you compare diagnostics stocks?
Ans. Test volumes, revenue per patient, operating margin and the number of collection centres matter most for operating performance. Price to earnings, return on equity, dividend yield and debt to equity show how the market values each company and how it is funded. Read each company’s filing for these along with the numbers in this article.
Which is the best diagnostics stock to buy among these five?
Ans. The best diagnostics stock depends on whether you value a national network, an asset-light partner model or a hospital-based business, because the five names differ on all three. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation; Krsnaa Diagnostics has the lowest price to earnings; Thyrocare has the highest return on equity as well as the highest dividend yield. No single stock tops every measure, and none of this is a recommendation. Use the tables to build a shortlist, check the latest filings, and speak to a SEBI-registered advisor before you decide, since your goals, time horizon and risk appetite matter more than any ranking.
